Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory marginal zone lymphoma after at least one anti-CD20-based regimen. FDA records list withdrawal of this indication on May 31, 2022.
LAMPGEN ANALYSIS
Why it matters
The accelerated decision was specific to an anti-CD20-exposed population and was later withdrawn.
What research teams should watch
Keep the initial approval and withdrawal dates linked in longitudinal analyses of available regimens.
PRIMARY RECORDS